ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

LLOY Lloyds Banking Group Plc

54.74
-1.34 (-2.39%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Lloyds Banking Group Plc LSE:LLOY London Ordinary Share GB0008706128 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.34 -2.39% 54.74 54.88 54.92 56.56 54.28 56.38 202,108,354 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Commercial Banks, Nec 23.74B 5.46B 0.0859 6.39 34.87B
Lloyds Banking Group Plc is listed in the Commercial Banks sector of the London Stock Exchange with ticker LLOY. The last closing price for Lloyds Banking was 56.08p. Over the last year, Lloyds Banking shares have traded in a share price range of 39.55p to 57.22p.

Lloyds Banking currently has 63,569,225,662 shares in issue. The market capitalisation of Lloyds Banking is £34.87 billion. Lloyds Banking has a price to earnings ratio (PE ratio) of 6.39.

Lloyds Banking Share Discussion Threads

Showing 345951 to 345967 of 429500 messages
Chat Pages: Latest  13844  13843  13842  13841  13840  13839  13838  13837  13836  13835  13834  13833  Older
DateSubjectAuthorDiscuss
31/1/2021
11:56
No mention of the damage caused by the BLM and ANTIFA nutters when campaigning for Sleepy Joe?
maxk
31/1/2021
11:48
Interstallar1 - Obviously from "The donkey party"
asterix96
31/1/2021
11:05
Lloy needs more than a clinic its in IC
scruff1
31/1/2021
11:03
Interesting times coming up get your popcorn ready...

Biden administration should sue Donald Trump to pay for Capitol riot cleanup

With well over 100 rioters already arrested, and major criminal investigations still in progress, it is time for the Biden administration to start efforts to recover the millions of dollars in cleanup and physical restoration costs owed the United States from the insurrection. In addition, those responsible for the invasion are also obligated to pay for the military, national guard and other Inauguration Day security expenses made necessary to assure that nothing like Jan. 6 happened at the swearing in. It is not likely that, even collectively, the individuals who have been arrested will begin to have enough money to scratch the surface of that debt.

But there is one person who is responsible, has the money, and for whom money talks: private citizen Donald J. Trump, who should be the lead defendant in a case to be brought by United States to reimburse the government for its monetary losses. Of course, despite his promise to join the rioters at the Capitol, the then-president was safely hiding out in the White House, but that will not relieve him of the legal liability for pulling the rhetorical trigger to start the invasion.

interstellar1
31/1/2021
10:34
Is this still a Lloyds topic only page or a clinic ??????????????
gambill
31/1/2021
10:32
Is this still a Lloyds topic only page or a clinic ??????????????
gambill
31/1/2021
10:22
Max - "Poikka is normally sound. Not sure whats got into him of late.


Your position is correct jl. Look after our own first. Just like everyone else"

Dear chap, I refer you to my post where I said, "In the meantime, the UK should carry on with its programme."

Quite clearly, I was saying just that, and if you had read on you'd have seen that I was expecting us to have a surplus, which, by inference, all would have meant that THEN we'd be in a position to help others.

I don't ask for much...

poikka
31/1/2021
09:55
837 all good ammunition for the UK Max. Bibens been abit quiet since the EU announced Huawei would be rolling out its 5G, Perhaps a vaccine donation to Ireland might stop is gob flapping quite so much.
utrickytrees
31/1/2021
09:40
Bloody hell freddie. The Graun finding fault with the €uro onion?


Von der Legover is in trouble.

maxk
31/1/2021
09:34
Its cured everything for 105k
scruff1
31/1/2021
09:34
Opinion
European Union
The Observer view on the vaccine dispute with Brussels
Observer editorial

Making a scapegoat of Britain can’t disguise the EU’s shambolic response to Covid-19 vaccine acquisition


The European commission’s U-turn over its reckless plan to effectively blockade the Ireland-Northern Ireland border is the latest humiliation suffered by Brussels amid an escalating firestorm sparked by Covid-19 vaccine supply shortages across Europe. The commission president, Ursula von der Leyen, has made a series of mistakes and misjudgments in handling the pandemic over the past year. This latest blunder will intensify doubts about her leadership.

It is extraordinary that Von der Leyen and senior colleagues did not appear to appreciate how unwise, and potentially dangerous for the Belfast-Good Friday agreement, was their move to impose back-door vaccine import controls on the UK using Brexit’s Northern Ireland protocol. This had to be personally spelled out to her by Boris Johnson and the Irish taoiseach, Micheál Martin. Both expressed “deep unhappiness” – code for utter fury and amazement.

The shambles in Brussels did not begin with this row, nor is Von der Leyen the only culprit. A palpable sense of panic has gripped EU leaders in recent days as public anger has understandably grown over Europe-wide vaccine shortfalls. In France, Spain and elsewhere, vaccination schedules are in turmoil. People in the most vulnerable groups are being turned away. As demands for an explanation rise, political blame-shifting has reached a new level.

AstraZeneca, the British-Swedish pharmaceutical company, has emerged as the scapegoat of choice for European politicians and bureaucrats anxious to avoid taking responsibility. Its outstanding success, sparked by a brilliant team of scientists and researchers at Oxford University, in producing a highly effective, easily administered, at-cost vaccine seems too much to stomach for the likes of Emmanuel Macron, France’s president.

In remarkably ill-informed comments, Macron regurgitated erroneous German claims
France has, sadly, failed to produce its own vaccine. Last week, the celebrated Pasteur Institute abandoned its main vaccine project, while the French pharma group, Sanofi, also admitted temporary defeat. French leaders have taken this hard. “It’s a sign of the decline of the country,” said Macron ally François Bayrou. He blamed the United States for a French “brain drain”.

Macron took aim elsewhere. In remarkably ill-informed comments on Friday, he regurgitated erroneous German claims that the Oxford-AstraZeneca vaccine in use in the UK was “ineffective” among people aged over 65. He also suggested, again without evidence, that the company, and the UK government, had engaged in “questionable behaviour”.

It’s no surprise that a French leader, down in the polls ahead of elections next year and feeling the heat, should unfairly pick on Britain. Less expected have been unhelpful interventions by other European politicians, notably German health minister, Jens Spahn. While Spahn amplified doubts about the Oxford-AstraZeneca vaccine, others were complaining, perversely, about supply cuts – all as the European regulator dithered over approving its use, which it finally did on Friday.

Low-quality European leadership has been a problem since the start of the pandemic. The commission belatedly realised last spring that it was in a global vaccine race, not least with Donald Trump. It allowed four countries – Germany, France, Italy and the Netherlands – to lead negotiations with possible suppliers. Then in June, Von der Leyen and her equally unimpressive health commissioner, Stella Kyriakides, fatefully changed their minds.

For political, not scientific reasons, the commission opted to involve all 27 members in vaccine acquisition
For political, not scientific or practical reasons, they opted to involve all 27 member states in vaccine acquisition decision-making, with the commission in overall charge – in order to demonstrate EU “solidarity” and the power of the single market. This led to an EU contract with AstraZeneca, ready for signature in June, being delayed until August. Other vaccine pre-orders were also held up. The US company Moderna warned in November that this approach would inevitably slow vaccine delivery across the EU.

The EU claim that AstraZeneca failed to honour its contractual obligations – the issue that has led it, against World Health Organization (WHO) advice, to introduce blanket controls on vaccine exports – must be seen in this context: panicky leadership in Brussels, national blame-games, bureaucratic and regulatory tardiness, post-Brexit anti-British animus and no-fault production problems, such as those experienced by Pfizer as well as AstraZeneca’s Belgian and Dutch plants. The WHO warns that Europe’s vaccine controls will prolong the global pandemic.

The vaccine crisis has shown the EU at its worst. By contrast, it has shown Britain at its best. Early government purchasing decisions were crucial. The rollout, overseen by Kate Bingham’s taskforce, has been efficiently managed so far by a grand coalition of NHS workers, GPs’ surgeries, pharmacies and volunteers. Now comes new data suggesting vaccinations are having a real impact in reducing infections and slowing the pandemic. Immunity is said to continue to build a month after a single dose is administered.

As of Friday, more than 11% of the UK population had been vaccinated compared with 2.3% in Germany and 1.8% in France. These figures give a stark measure of relative EU incapacity. At the end of a week that saw a grim milestone of 100,000 Covid deaths in Britain, the UK’s vaccine success story is a bright star in a gloomy firmament. Incompetence in Brussels must by no means be allowed to obstruct this encouraging progress. As for the EU, it should get its house in order – quickly.





That can't have been easy for them to publish that.

freddie01
31/1/2021
09:27
Fair enough PC.


Altho another way of looking at it is they have recorded everything as C19.

The figs they are bandying about are seriously bent imo.

maxk
31/1/2021
09:24
Von der has probably helped in more ways than one. Even though we didn't need to call on the US to get involved one can be certain that Biden was watching with interest. His view towards the EU will surely have been sharpened as a result of this episode. Johnson deserves due credit.
patientcapital
31/1/2021
09:20
No maxk. Merely commenting that because of measures taken to contain Covid a side effect has been to contain another infectious disease even if it is a double edged sword. There are two hotspots in Asia which is potentially helpful as 'flu jab developers usually look to Asian strains when working out what to made for the following season.
patientcapital
31/1/2021
08:50
Would that be prison Porty ? :-)
scruff1
31/1/2021
08:40
Are you saying C19 is a cure for common or garden flu?
maxk
31/1/2021
08:23
Influenza all but wiped out this season with a 95% drop in infections. Good news and bad. With so few cases to work with those developing next season's jabs have few pointers on which strain to target. Immunity will have been greatly reduced as well meaning that the potential for the disease to be severe next season is heightened.
patientcapital
Chat Pages: Latest  13844  13843  13842  13841  13840  13839  13838  13837  13836  13835  13834  13833  Older